StoxMankind Pharma vs Max Healthcare Institute: share price & financials comparison
NSE: MANKIND vs MAXHEALTH · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Mankind Pharma vs Max Healthcare Institute at a glance
Mankind Pharma (MANKIND) has a market capitalisation of ₹1,04,902 Cr, against ₹90,907 Cr for Max Healthcare Institute (MAXHEALTH). Over the past year Mankind Pharma has returned +3.9%, compared with -21.5% for Max Healthcare Institute. On valuation, Mankind Pharma trades at a lower P/E of 46.7 versus 65.8. Mankind Pharma earns a higher return on equity (12.8% vs 12.2%). Mankind Pharma comes out ahead on size, valuation, financial health and technicals. Max Healthcare Institute comes out ahead on profitability and growth. Across the scored metrics below, Mankind Pharma leads on 9 and Max Healthcare Institute on 7. On StoxGud's 10-point checklist, Mankind Pharma scores 7/10 and Max Healthcare Institute scores 3/10.
| Metric | Mankind Pharma | Max Healthcare Institute |
|---|---|---|
| Size | ||
| Market cap | ₹1,04,902 Cr | ₹90,907 Cr |
| Revenue (latest FY) | ₹14,278 Cr | ₹8,373 Cr |
| Net profit (latest FY) | ₹1,913 Cr | ₹1,442 Cr |
| Valuation | ||
| P/E | 46.7 | 65.8 |
| P/B | 5.97 | 8.02 |
| Dividend yield | 0.04% | 0.16% |
| Profitability | ||
| Return on equity | 12.8% | 12.2% |
| Net profit margin | 14.6% | 15.1% |
| Operating margin | 26.5% | 26.8% |
| Growth | ||
| Revenue growth (YoY) | +17.3% | +20.3% |
| Net profit growth (YoY) | +39.1% | -15.5% |
| Revenue CAGR (multi-year) | +17.7% | +27.3% |
| Financial health | ||
| Debt to equity | 0.31 | 0.33 |
| Momentum | ||
| 1-month return | +1.6% | +2.9% |
| 1-year return | +3.9% | -21.5% |
| 3-year CAGR | +13.0% | +16.3% |
| 5-year CAGR | — | +22.5% |
| Distance from 52W high | -3.0% | -20.9% |
| Technicals | ||
| RSI (14) | 72 | 79 |
| Price vs 200-day avg | +9.5% | -7.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Mankind Pharma | Max Healthcare Institute |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 7/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Mankind Pharma or Max Healthcare Institute?
Mankind Pharma has a market cap of ₹1,04,902 Cr and Max Healthcare Institute has a market cap of ₹90,907 Cr as of 06 Nov 2026.
Which has a lower P/E, Mankind Pharma or Max Healthcare Institute?
Mankind Pharma has the lower P/E: Mankind Pharma trades at 46.7 and Max Healthcare Institute at 65.8.
Which gave better returns in the last year, Mankind Pharma or Max Healthcare Institute?
Mankind Pharma did better: Mankind Pharma returned +3.9% and Max Healthcare Institute returned -21.5% over one year.
Is Mankind Pharma or Max Healthcare Institute a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Mankind Pharma scores 7/10 and Max Healthcare Institute scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.